NCT05162638
Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation
Enrolling by Invitation
NAAges 18–40InterventionalUniversity of PennsylvaniaInvestigator-initiated
~24 participants
Updated 2026-01-09 on ClinicalTrials.gov
What's tested:thoracic duct cannulation
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Tolerability
Measured over up to 21 days
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Amit Bar-Or, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
1\. Participants suspected of not being able or willing to cooperate or comply with study protocol requirements in the opinion of the investigator.
What this trial measures
- Safety and Tolerabilityup to 21 days
Quantified as percent of the study population experiencing serious adverse event from in-and-out catherization procedure and from "indwelling" catheterization procedure
- B Cellsup to 21 days
Change in proportion of flow cytometry defined naïve (CD27-) and memory (CD27+) B cells in thoracic duct of patients with MS prior to and following anti-CD20 therapy with Ofatumumab